Meeder Asset Management Inc Regeneron Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

$1.43 Billion
Q4 2024

A detailed history of Meeder Asset Management Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Meeder Asset Management Inc holds 30 shares of REGN stock, worth $21,225. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 204 85.29%

Holding current value

$21,225

Previous $214,000 90.19%

% of portfolio

0.0%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 12, 2025	SELL	$701.85 - $1046.91 $122,121 - $182,162	-174 Reduced 85.29%	30 $21,000
Q3 2024 Nov 07, 2024	BUY	$1024.09 - $1201.76 $181,263 - $212,711	177 Added 655.56%	204 $214,000
Q2 2024 Aug 08, 2024	SELL	$883.2 - $1071.19 $189,004 - $229,234	-214 Reduced 88.8%	27 $28,000
Q1 2024 May 07, 2024	BUY	$902.69 - $993.35 $217,548 - $239,397	241 New	241 $231,000
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $3.37 Million - $3.99 Million	-4,811 Reduced 99.67%	16 $11,000
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $22,456 - $27,290	-33 Reduced 0.68%	4,827 $3.97 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $855,538 - $928,864	-1,212 Reduced 19.96%	4,860 $3.51 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $586,023 - $739,530	-1,021 Reduced 14.39%	6,072 $4.18 Million
Q2 2022 Aug 08, 2022	BUY	$548.35 - $738.84 $334,493 - $450,692	610 Added 9.41%	7,093 $4.19 Million
Q1 2022 May 10, 2022	SELL	$595.12 - $698.43 $4.83 Million - $5.66 Million	-8,108 Reduced 55.57%	6,483 $4.53 Million
Q4 2021 Feb 11, 2022	SELL	$543.48 - $670.97 $1.19 Million - $1.47 Million	-2,192 Reduced 13.06%	14,591 $9.22 Million
Q3 2021 Nov 08, 2021	BUY	$574.03 - $680.96 $898,356 - $1.07 Million	1,565 Added 10.28%	16,783 $10.2 Million
Q2 2021 Aug 09, 2021	SELL	$472.8 - $558.54 $879,408 - $1.04 Million	-1,860 Reduced 10.89%	15,218 $8.5 Million
Q1 2021 Apr 28, 2021	BUY	$446.73 - $548.2 $7.45 Million - $9.15 Million	16,682 Added 4212.63%	17,078 $8.08 Million
Q4 2020 Feb 09, 2021	SELL	$478.3 - $607.98 $2.12 Million - $2.69 Million	-4,429 Reduced 91.79%	396 $191,000
Q3 2020 Nov 02, 2020	BUY	$544.75 - $658.21 $34,864 - $42,125	64 Added 1.34%	4,825 $2.7 Million
Q2 2020 Aug 11, 2020	SELL	$493.32 - $643.92 $4,439 - $5,795	-9 Reduced 0.19%	4,761 $2.97 Million
Q1 2020 May 15, 2020	SELL	$336.18 - $494.43 $1.72 Million - $2.52 Million	-5,102 Reduced 51.68%	4,770 $2.33 Million
Q4 2019 Feb 13, 2020	BUY	$274.13 - $376.51 $2.52 Million - $3.47 Million	9,204 Added 1377.84%	9,872 $3.71 Million
Q3 2019 Oct 17, 2019	SELL	$273.46 - $318.39 $100,906 - $117,485	-369 Reduced 35.58%	668 $185,000
Q2 2019 Aug 05, 2019	SELL	$299.6 - $414.82 $3.98 Million - $5.51 Million	-13,279 Reduced 92.76%	1,037 $325,000
Q1 2019 Apr 16, 2019	BUY	$372.08 - $439.57 $498,959 - $589,463	1,341 Added 10.34%	14,316 $5.88 Million
Q4 2018 Jan 17, 2019	BUY	$335.82 - $403.04 $1.63 Million - $1.96 Million	4,858 Added 59.85%	12,975 $4.85 Million
Q3 2018 Nov 02, 2018	BUY	$351.14 - $408.51 $2.26 Million - $2.63 Million	6,426 Added 380.01%	8,117 $0
Q2 2018 Jul 24, 2018	BUY	$284.6 - $344.99 $227,395 - $275,647	799 Added 89.57%	1,691 $0
Q1 2018 May 03, 2018	SELL	$315.82 - $393.78 $179,069 - $223,273	-567 Reduced 38.86%	892 $307,000
Q4 2017 Feb 02, 2018	SELL	$358.63 - $469.95 $595,684 - $780,586	-1,661 Reduced 53.24%	1,459 $549,000
Q3 2017 Oct 20, 2017	BUY	$431.38 - $504.0 $1.35 Million - $1.57 Million	3,120	3,120 $1.4 Million

Others Institutions Holding REGN

# of Institutions

1,492

Shares Held

85.8M

Call Options Held

1.53M

Put Options Held

1.44M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.8B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.

Account

Meeder Asset Management Inc Regeneron Pharmaceuticals, Inc. Transaction History